The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents, according to a retrospective cohort ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...

Myeloma Trial Results Spark Talk of 'Potential Cure' — One-third of patients alive and progression-free 5 or more years after a single infusion ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

As the future of rare disease research at Cincinnati Children's is threatened, parents of 13-year-old Charlie Evans plead for its reinstatement.